MetaHeps GmbH provides consulting and solutions for drug-induced liver injury (DILI) in clinical drug development and postmarketing. They generate personalized cell models that reflect individual drug hepatotoxicity from small patient blood samples. Their customers include research-driven pharmaceutical companies and global CROs, who use MetaHeps' services in clinical phases of drug development and postmarketing to diagnose or exclude DILI in individual patients. MetaHeps' innovative approach aims to address DILI issues in drug development, ultimately increasing patient access to novel drugs.